Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Efficacy of the Addition of TRAstuzumab and Pertuzumab to Neoadjuvant Chemoradiation: a Randomized Multi-center Study in Resectable HER2 Overexpressing Adenocarcinoma of the Esophagus or Gastroesophageal Junction. The TRAP-2 Study

NCT05188313 is registered in ClinicalTrials.gov with Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) as lead sponsor.

NCT NCT05188313
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05188313 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Efficacy of the Addition of TRAstuzumab and Pertuzumab to Neoadjuvant Chemoradiation: a Randomized Multi-center Study in Resectable HER2 Overexpressing Adenocarcinoma of the Esophagus or Gastroesophageal Junction. The TRAP-2 Study
Lead sponsor
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Phase
Phase 3
Overall status
Recruiting
Start date
March 9, 2022
Completion date
February 28, 2037
Enrollment
376 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

esophageal adenocarcinoma, esophageal cancer